THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Lobbying for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $3,490,000.00 expenses · posted Apr 20, 2026

Official filing document

Bills named in this filing 11

HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
HR 6400
Rx ACCESS Act
S 4106
Rx ACCESS Act
S 1542
Uyghur Policy Act of 2025
HR 2214
DRUG Act
HR 5378
Tribal Healthcare Careers Act
S 1339
Stop CCP Money Laundering Act of 2025
S 526
Pharmacy Benefit Manager Transparency Act of 2025
HR 7148
Consolidated Appropriations Act, 2026
HR 5582
Patients Deserve Price Tags Act
S 2355
Patients Deserve Price Tags Act

Lobbying activity 5

Health Issues

Issues relating to implementation of the No Surprises Act

Defense

H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act

Medicare/Medicaid

Issues related to prior authorization; ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) model

Pharmacy

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act

Labor Issues/Antitrust/Workplace

Issues related to competition in the health care marketplace.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.